Targeting NOX4 disrupts the resistance of papillary thyroid carcinoma to chemotherapeutic drugs and lenvatinib
Advanced differentiated thyroid cancer cells are subjected to extreme nutritional starvation which contributes to develop resistance to treatments; however, the underlying mechanism remains unclear. Cells were subjected to serum deprivation by culture in medium containing 0.5% fetal bovine serum. A...
Main Authors: | Dang, H. (Author), Hu, J. (Author), Kang, Y. (Author), Peng, X. (Author), Sheng, J. (Author), Tang, P. (Author), Wu, B. (Author), Xu, T. (Author), Zhang, R. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2022
|
Online Access: | View Fulltext in Publisher |
Similar Items
-
Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma
by: Haruhiko Yamazaki, et al.
Published: (2019-10-01) -
Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
by: Masaki Takinami, et al.
Published: (2020-05-01) -
A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy
by: Hiroyuki Iwasaki, et al.
Published: (2020-01-01) -
Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
by: Yasuko Hyogo, et al.
Published: (2018-11-01) -
Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma
by: Phillip J. Groden, et al.
Published: (2018-02-01)